Bharat Biotech in tie-up with the US-based company FluGen and University of Wisconsin Madison to develop a vaccine named “Coro-Flu” to fight against COVID-19. CoroFlu will build on the backbone of FluGen’s flu vaccine candidate known as M2SR.
Click Here To Get Test Series For SBI PO 2020
The vaccine is being developed on the basis of FluGen’s flu vaccine candidate known as M2SR, a self-limited version of the influenza virus. It induces an immune response against the flu. The vaccine will be built by FluGen’s lab that inserts gene sequences from SARS-CoV-2, the novel coronavirus that causes the disease COVID-19 into M2SR so that the novel vaccine will also induce immunity against the coronavirus.
Important takeaways for all competitive exams:
World AIDS Vaccine Day, also known as HIV Vaccine Awareness Day, is observed annually on…
The Indian government has announced plans for public sector companies like Coal India, NMDC, and…
In April, India's merchandise exports saw a modest 1% increase, reaching $34.99 billion, driven by…
The Open Network for Digital Commerce (ONDC), a digital infrastructure initiative launched in 2021, has…
In response to rising credit demand and falling liquidity, State Bank of India (SBI) has…
The Indian Army is poised to elevate its air defense capabilities with the impending delivery…